2024 Full-year results and business update
– Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part expected in Q2 2025
– Randomization in Phase II part of the Phase I/II trial evaluating TG4050 in head and neck cancer patients due to be completed in Q4 2025
– New trial with individualized cancer vaccine planned to start in Q4 2025 in a second indication
– Business funded until the end of April 2026
Conference call scheduled today at 6 p.m. CET (in English). See details below.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer